ADDF launched the third phase of its Diagnostics
Author: Michael
Serina Therapeutics has entered definitive agreem
Company designates target in metabolic disease p
Edinburgh scientists use engineered bacteria to
How DLT’s chatbot turns fragmented public mark
Today we are lifting the lid on what this really
High-stakes debate and hackathon will probe brai
UT Health San Antonio readies for $38 million hu
Surprise cancelation of leading aging conference
Alchemab Therapeutics has appointed Ulrich Wendt,